-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related death, with the highest incidence in East Asian populations worldwide
Helicobacter pylori (H.
H.
Eradication of Helicobacter pylori can reduce the risk of stomach cancer!
Eradication of Helicobacter pylori can reduce the risk of stomach cancer! Eradication of Helicobacter pylori can reduce the risk of stomach cancer!Intestinal metaplasia is considered to be an adaptive response of the gastric mucosa to a long-term adverse environment, and during the regeneration process, the dysplastic intestinal epithelium further develops abnormally, forming atypical hyperplasia, which is manifested by cellular atypia and glandular structural disorder.
A study published in the journal Gastroenterology evaluated the long-term effects of H.
To assess the long-term effects of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in a high-risk population
This is a prospective, randomized, placebo-controlled clinical trial conducted in southern China with high risk of gastric cancer
Cumulative incidence of gastric cancer between the two groups in the total population (A) and the population without precancerous lesions (B)
Cumulative incidence of gastric cancer between the two groups in the total population (A) and the population without precancerous lesions (B)During 26.
The incidence of gastric cancer was lower in H.
Summary diagram
Summary diagramTherefore, eradication of H.
So, how to eradicate Hp?
So, how to eradicate Hp? So, how to eradicate Hp?Gastritis caused by H.
H.
Overall, H.
Bismuth quadruple regimen as the main empirical treatment for H.
Note: a standard dose of proton pump inhibitor + standard dose of bismuth (2 times a day, orally one hour before meals) + 2 kinds of antibacterial drugs (orally after meals)
Note: a standard dose of proton pump inhibitor + standard dose of bismuth (2 times a day, orally one hour before meals) + 2 kinds of antibacterial drugs (orally after meals)
Except that the regimen containing levofloxacin is not used as the initial treatment regimen, the eradication treatment is not divided into first-line or second-line treatment, and the regimen with high efficacy should be used for the initial treatment as much as possible
.
The recommended duration of empiric bismuth quadruple therapy is 14 days, unless local studies confirm that 10 days of treatment is effective (eradication rate >90%)
In addition, the choice of regimen should weigh efficacy, cost, potential adverse effects and drug availability, and make an individualized decision
.
After the initial treatment fails, one of the remaining options can be selected for salvage therapy
.
The choice of regimen should be based on the local H.
pylori antimicrobial resistance rate and personal drug use history, weighing the efficacy, drug cost, adverse reactions and drug availability
.
Even if H.
pylori is completely cured, it cannot be relaxed, and there is still the possibility of recurrence if you do not pay attention
.
pylori is completely cured, it cannot be relaxed, and there is still the possibility of recurrence if you do not pay attention
.
References: 1.
Yan Lingjun, Chen Ying, Chen Fa et al.
Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report from a Randomized Controlled Trial with 26.
5 Years of Follow-up.
[J] .
Gastroenterology, 2022, https ://doi.
org/10.
1053/j.
gastro.
2022.
03.
039
Yan Lingjun, Chen Ying, Chen Fa et al.
Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report from a Randomized Controlled Trial with 26.
5 Years of Follow-up.
[J] .
Gastroenterology, 2022, https ://doi.
org/10.
1053/j.
gastro.
2022.
03.
039
2.
Han Baohai.
Research progress on the relationship between Hp and digestive tract diseases [J].
China Urban and Rural Enterprise Health, 2020, 35(04): 51-4.
Han Baohai.
Research progress on the relationship between Hp and digestive tract diseases [J].
China Urban and Rural Enterprise Health, 2020, 35(04): 51-4
.
Leave a message here